EHA2026レポート① Late-breaking Session

再発・難治性CLL/SLL、
ベネトクラクス＋リツキシマブへの
ピルトブルチニブ追加で増悪・死亡リスク45％低下 Fixed-duration pirtobrutinib plus venetoclax–rituximab versus venetoclax–rituximab for patients with previously treated CLL/SLL: A phase 3, randomized trial (BRUIN CLL-322) (#LB5001)

Matthew S. Davids（Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA）